Abstract
Epithelial ovarian cancer remains a major women's health problem due to its high lethality. Despite great efforts to develop effective prevention and early detection strategies, most patients are still diagnosed at advanced stages of disease. This pattern of late presentation has resulted in significant challenges in terms of designing effective therapies to achieve long-term cure. One potential promising strategy is the application of targeted therapeutics that exploit a myriad of critical pathways involved in tumorigenesis and metastasis. This review examines three of the most provocative targeted therapies with current or future applicability in epithelial ovarian cancer.
Highlights
Ovarian cancer represents the sixth most common malignancy as well as the seventh leading cause of cancer-related death in women worldwide [1, 2]
This review examines three of the most provocative targeted therapies with current or future applicability in epithelial ovarian cancer
The present article addresses targeted therapies currently being employed or tested in epithelial ovarian cancer (EOC). Since their number has become as numerous as the Journal of Oncology myriad of critical pathways involved in ovarian neoplastic transformation, this review will focus on three of the most promising and/or well-studied targeted weapons in ovarian cancer therapeutics to date, namely, (i) antiangiogenesis compounds, (ii) epidermal growth factor receptor (EGFR) antagonists, (iii) poly (ADP) ribose polymerase (PARP) inhibitors
Summary
Ovarian cancer represents the sixth most common malignancy as well as the seventh leading cause of cancer-related death in women worldwide [1, 2]. Since “nonspecific” therapies, namely, surgery, radiation, and conventional chemotherapy, have largely failed to achieve cure in the majority of patients affected by epithelial ovarian cancer, investigators have focused on developing novel treatment approaches. Many of these new strategies are based upon an understanding of the critical molecules and pathways involved in tumorigenesis and metastasis. The present article addresses targeted therapies currently being employed or tested in epithelial ovarian cancer (EOC) Since their number has become as numerous as the Journal of Oncology myriad of critical pathways involved in ovarian neoplastic transformation, this review will focus on three of the most promising and/or well-studied targeted weapons in ovarian cancer therapeutics to date, namely,.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
